Benidipine Hydrochloride (Coniel) is a long-acting dihydropyridine calcium channel blocker, which is widely used clinically for the treatment of hypertension and angina pectoris. It inhibits calcium ion influx and dilates blood vessels, thereby lowering blood pressure and increasing myocardial blood supply.
Dosage and Administration & Recommended Dose of Benidipine Hydrochloride (Coniel)
Treatment of Hypertension
(1) For patients with hypertension (including renal parenchymal hypertension), the usual adult dose of Benidipine Hydrochloride is 2-4 mg once daily, to be taken orally after breakfast. The dose may be appropriately adjusted according to the patient's age and specific condition.
(2) If the therapeutic effect is unsatisfactory, the dose may be increased to 8 mg once daily under the guidance of a physician. For patients with severe hypertension, an initial dose of 4-8 mg once daily, also administered after breakfast, is generally recommended.
Treatment of Angina Pectoris
(1) For angina pectoris, the usual adult dose is 4 mg twice daily, to be taken orally after breakfast and dinner respectively. The dose should also be appropriately adjusted based on individual conditions and therapeutic responses.
(2) It should be noted that this product is a prescription drug and must be administered in strict accordance with the doctor's advice. The dose or frequency of administration shall not be increased, decreased or altered without medical guidance.
Dose Adjustment of Benidipine Hydrochloride (Coniel)
Efficacy-based Dose Adjustment
(1) Initial treatment should usually start with a low dose.
(2) Blood pressure or the frequency of angina pectoris attacks shall be monitored regularly after medication.
(3) If blood pressure control is not achieved or the improvement of angina pectoris symptoms is insignificant, the dose may be considered for gradual escalation after evaluation by a physician.
(4) The maximum dose for hypertensive patients can be increased to 8 mg per day.
Safety-based Dose Adjustment
(1) Close observation is required for adverse reactions during medication, such as excessive hypotension, headache, flushing, edema and elevated liver enzymes.
(2) In case of intolerable side effects, dose reduction or temporary suspension of medication should be considered, and a physician shall be consulted promptly.
Dose Adjustment for Drug Interactions
(1) Increased plasma concentration and enhanced antihypertensive effect: Co-administration with itraconazole, cimetidine, or consumption of grapefruit juice may lead to excessive hypotension. In such cases, close blood pressure monitoring is necessary, and the dose of this product should be reduced if needed.
(2) Decreased plasma concentration and diminished efficacy: Co-administration with rifampicin may result in reduced antihypertensive effect. Blood pressure should be monitored and dose adjustment shall be considered accordingly.
(3) Effect on digoxin concentration: Concomitant use may increase the plasma concentration of digoxin and raise the risk of digoxin toxicity. Plasma digoxin concentration and cardiac function should be monitored, and the doses of digoxin or this product shall be adjusted correspondingly.
Administration in Special Populations for Benidipine Hydrochloride (Coniel)
Geriatric Patients
(1) Geriatric patients have impaired physiological functions and are more sensitive to the drug, with an increased risk of adverse reactions such as hypotension.
(2) A lower initial dose (e.g., 2 mg per day) is recommended, with slow dose titration, and enhanced blood pressure monitoring after medication is required.
Pregnant and Lactating Women
(1) Pregnant women: This product is contraindicated in pregnant women or women of childbearing potential. Animal studies have shown that the drug can cross the placenta and pose potential risks to the fetus.
(2) Lactating women: The drug is excreted in breast milk and may pose potential risks to infants. Lactating women should avoid using this product; if administration is necessary, breastfeeding must be discontinued.
